featured
Bevacizumab Plus Paclitaxel vs Placebo Plus Paclitaxel as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bevacizumab Plus Paclitaxel Versus Placebo Plus Paclitaxel as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MERiDiAN): A Double-Blind Placebo-Controlled Randomised Phase III Trial With Prospective Biomarker Evaluation
Eur. J. Cancer 2016 Nov 04;[EPub Ahead of Print], D Miles, D Cameron, I Bondarenko, L Manzyuk, JC Alcedo, RI Lopez, SA Im, JL Canon, Y Shparyk, DA Yardley, N Masuda, J Ro, N Denduluri, S Hubeaux, C Quah, C Bais, J O'ShaughnessyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.